Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04893785
Title A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) (CABOTEM)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute, Naples
Indications

gastrointestinal neuroendocrine tumor

islet cell tumor

pulmonary neuroendocrine tumor

Therapies

Cabozantinib + Temozolomide

Age Groups: adult | senior
Covered Countries ITA


No variant requirements are available.